ACE and hypertensive disorder: The most active peptide, i.e., MVPYPQR had ACE-inhibitory IC50 values of 30 μM in addition to antioxidant activity (8933.05 μM TE mg−1 peptide) Inhibition of ACE activity is considered an active therapy to reduce hypertension concerns.